[HTML][HTML] Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
JM Gelfand, BAC Cree, SL Hauser - Neurotherapeutics, 2017 - search.proquest.com
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
[引用][C] Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
JM Gelfand, BAC Cree, SL Hauser - Neurotherapeutics, 2017 - cir.nii.ac.jp
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.
JM Gelfand, BAC Cree, SL Hauser - Neurotherapeutics: the Journal …, 2017 - europepmc.org
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
[HTML][HTML] Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
JM Gelfand, BAC Cree, SL Hauser - Neurotherapeutics, 2017 - ncbi.nlm.nih.gov
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
[HTML][HTML] Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
JM Gelfand, BAC Cree… - …, 2017 - neurotherapeuticsjournal.org
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
[HTML][HTML] Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
JM Gelfand, BAC Cree, SL Hauser - Neurotherapeutics, 2017 - Springer
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.
JM Gelfand, BAC Cree, SL Hauser - … : the journal of the American …, 2017 - escholarship.org
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
JM Gelfand, BAC Cree… - … : the journal of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …
in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and …